Associated Papers
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Sohn SH et al.
Cancers, 2022
35884507 (PubMed )
Supplement: cancers-14-03444-s001.zip › supplementary_material_Table_S1.xlsx › Hs746T
Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform.
Lee P et al.
International Journal of Molecular Sciences, 2022
35563039 (PubMed )
Supplement: ijms-23-04647-s001.zip › Supplemental_file_S5.xlsx › Supp_Table_S3
Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors.
Grzywa TM et al.
International Journal of Molecular Sciences, 2021
Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia.
Wu N et al.
Journal of Cellular and Molecular Medicine, 2020
32277576 (PubMed )
Supplement: JCMM-24-4931-s010.xlsx › Sheet1
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.
Suarez-Kelly LP et al.
Cold Spring Harbor Molecular Case Studies, 2018
29449315 (PubMed )
Supplement: supp_mcs.a002352_Supplemental_Table_3.xls › SuppTable3.modified.20171216
Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.
Smetana J et al.
Molecular Cytogenetics, 2018
29375670 (PubMed )
Supplement: 13039_2018_357_MOESM2_ESM.xlsx › variants
EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms.
Sanpaolo E et al.
Endocrine, 2016
Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.
Bachmann N et al.
The Prostate, 2005
Select a paper to view details